Julian Engel v. Novex Biotech, LLC

689 F. App'x 510
CourtCourt of Appeals for the Ninth Circuit
DecidedApril 21, 2017
Docket15-15492
StatusUnpublished
Cited by4 cases

This text of 689 F. App'x 510 (Julian Engel v. Novex Biotech, LLC) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Julian Engel v. Novex Biotech, LLC, 689 F. App'x 510 (9th Cir. 2017).

Opinion

MEMORANDUM **

Julian Engel appeals from the district court judgment dismissing his second amended complaint for failing to state a claim upon which relief can be granted. We have jurisdiction under 28 U.S.C. § 1291, and we affirm.

For the reasons stated in a concurrently filed opinion in Serena Kwan, et al. v. SanMedica International, No. 15-15496, 1 the district court correctly applied established California law. Neither California’s Unfair Competition Law (‘the UCL”) nor its Consumer Legal Remedies Act (“the CLRA”) provides consumers with a private cause of action to enforce the substantiation provisions of California’s unfair competition or consumer protection laws.

As in Kwan, the district court did not err in concluding that Engel’s second amended complaint did not allege sufficient facts to support a claim that defendant’s advertising claims were actually false. The second amended complaint rests on allegations that defendant’s marketing claims are not supported by any reliable clinical trials and that a comprehensive search could not produce any publication to support claims that defendant’s product, Growth Factor-9, was clinically tested as claimed on its packaging. These allegations do not support a finding that the advertis *511 ing claims are actually false, only that they lack substantiation. As it did in Kwan, the district court appropriately declined En-gel’s invitation to incorporate Lanham Act analysis into California consumer protection law. The district court did not err in granting the motion to dismiss Engel’s second amended complaint.

Further, as in Kwan, the district court provided ample guidance for Engel to allege successfully a claim of actual falsehood when it dismissed the first amended complaint with leave to amend. Therefore, the court did not err in dismissing the second amended complaint with prejudice.

AFFIRMED.

**

This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3.

1

. For purposes of oral argument only, we consolidated this appeal with the appeal in Kwan.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
689 F. App'x 510, Counsel Stack Legal Research, https://law.counselstack.com/opinion/julian-engel-v-novex-biotech-llc-ca9-2017.